The firm looks to position its Halo lung assay for detecting cancers not found by LDCT and in average-risk populations for which LDCT screening is not currently recommended.

The approval allows the company to offer its PD-L1 IHC 22C3 pharmDx Code SK006 CDx for ovarian and other cancers.

The IVDR encompasses the firm's ER, PR, and Ki67 testing and completes certification of its overall digital pathology breast suite.

The lab firm said it now expects full-year net revenue in the range of $11.95 billion to $12.05 billion, up from its previous guidance of $11.78 billion to $11.90 billion.

Precision Diabetes said on Thursday that it has acquired the exclusive US commercial rights to Nagase Diagnostics' Lucica Glycated Albumin-L assay for diabetes management. Financial and other terms of ...

The second generation test can detect the Bundibugyo strain of the virus that currently poses a threat in the Democratic Republic of the Congo and nearby countries.

The tests will help identify the inflammatory pathways involved in patients with COPD and asthma to help better guide therapy selection.

According to DOJ, the company provided consulting services at below market value to certain health care providers that referred patients to NeoGenomics for lab testing.

The firm is developing blood-based early cancer detection tests for a variety of indications, including colorectal cancer and lung cancer.

The tests are intended for infectious and chronic disease detection and diagnosis as well as to aid in routine health monitoring.

Burning Rock will add the prostate Genomic Instability Score (prGIS) algorithm to its myChoice HRD Plus assay and will develop new HRD tests on its OncoScreen Plus platform.